Fulcrum Therapeutics, Inc. (NASDAQ:FULC) to Post Q3 2024 Earnings of ($0.38) Per Share, HC Wainwright Forecasts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities research analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Fulcrum Therapeutics in a note issued to investors on Thursday, August 1st. HC Wainwright analyst A. Fein now expects that the company will earn ($0.38) per share for the quarter, up from their prior estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at $0.13 EPS and FY2028 earnings at $0.58 EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%.

FULC has been the topic of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $23.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, July 10th. The Goldman Sachs Group raised Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $6.00 to $15.00 in a research note on Monday, May 13th. Finally, Oppenheimer dropped their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, May 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $15.57.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $8.87 on Monday. The firm has a market cap of $553.49 million, a P/E ratio of -5.57 and a beta of 2.29. Fulcrum Therapeutics has a 1 year low of $3.14 and a 1 year high of $13.70. The firm’s 50 day moving average price is $7.60 and its 200 day moving average price is $8.24.

Hedge Funds Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. National Bank of Canada FI lifted its stake in shares of Fulcrum Therapeutics by 869.6% during the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after purchasing an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Fulcrum Therapeutics by 348.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,150 shares of the company’s stock worth $48,000 after purchasing an additional 5,556 shares during the period. Capstone Investment Advisors LLC acquired a new stake in Fulcrum Therapeutics during the fourth quarter worth about $68,000. SG Americas Securities LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $115,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics in the 2nd quarter worth approximately $130,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.